sli-f06
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 18, 2019 (NCT03880058)
Timeline
Indications
Studied for
Mechanism of action
- FibromodulinACTIVATOR
FMOD activator
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05501327 | Phase 2 | Jul 25, 2022 | Scarless Laboratories, Inc. |
| NCT03880058 | Phase 1/Phase 2 (Phase 2) | Mar 18, 2019 | ethica Clinical Research Inc., Scarless Laboratories, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Scarless Laboratories, Inc. | For profit | 2 | 2 | 1 | 2019 |
| ethica Clinical Research Inc. | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1